Physician profile
Yan Wang
NPI 1588752521
$4,014.97
in general payments reported to CMS, 2019-2025
18 companies · $623 in 2025
The $623 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,509 · 2020: $42.31 · 2021: $129 · 2022: $657 · 2023: $449 · 2024: $607 · 2025: $623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,679.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,678.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,288.19 | 2019-2025 | Rinvoq |
| Janssen Biotech, INC. | $1,014.97 | 2019-2025 | Tremfya |
| Janssen Scientific Affairs, LLC | $370.54 | 2019-2022 | |
| Lilly USA, LLC | $241.57 | 2019-2022 | |
| Helsinn Therapeutics (U.S.), INC. | $201.21 | 2021-2025 | Valchlor |
| Merz North America, INC. | $177.47 | 2022 | |
| Celgene Corporation | $133.26 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $102.67 | 2022 | |
| Sun Pharmaceutical Industries INC. | $95.27 | 2022-2025 | Ilumya |
| Incyte Corporation | $81.26 | 2025 | Opzelura |
| Genzyme Corporation | $76.09 | 2024-2025 | |
| Gilead Sciences, INC. | $69.00 | 2019 | |
| Leo Pharma INC. | $60.50 | 2021-2023 | Adbry |
| Pfizer INC. | $23.97 | 2025 | |
| Amgen INC. | $23.51 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $22.05 | 2025 | Collagenase Santyl |
| Arcutis Biotherapeutics, INC. | $17.72 | 2023 | |
| Organon LLC | $15.72 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yan Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.